Teva Pharmaceutical Industries Ltd (NYSE:TEVA)’s share price hit a new 52-week low during mid-day trading on Wednesday after Cantor Fitzgerald lowered their price target on the stock from $16.00 to $9.00. Cantor Fitzgerald currently has a neutral rating on the stock. Teva Pharmaceutical Industries traded as low as $8.25 and last traded at $8.47, with a volume of 13081936 shares traded. The stock had previously closed at $9.08.

A number of other equities analysts have also recently issued reports on TEVA. Wells Fargo & Co reissued a “hold” rating and issued a $20.00 target price (down previously from $24.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, February 14th. They noted that the move was a valuation call. Maxim Group reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 14th. Raymond James raised shares of Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $22.00 target price on the stock in a report on Thursday, February 14th. Credit Suisse Group cut their target price on shares of Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating on the stock in a report on Thursday, February 14th. Finally, Mizuho cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and cut their target price for the stock from $25.00 to $18.00 in a report on Wednesday, February 20th. Five analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $17.05.

In other Teva Pharmaceutical Industries news, VP Notaristefani Carlo De sold 16,070 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.42, for a total value of $183,519.40. Following the sale, the vice president now owns 49,659 shares in the company, valued at $567,105.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sol J. Barer purchased 111,000 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was purchased at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the purchase, the director now directly owns 115,942 shares of the company’s stock, valued at approximately $1,041,159.16. The disclosure for this purchase can be found here. Insiders sold 18,860 shares of company stock worth $226,854 in the last 90 days. 0.49% of the stock is owned by company insiders.

Several large investors have recently made changes to their positions in the business. FMR LLC increased its stake in shares of Teva Pharmaceutical Industries by 44.0% during the fourth quarter. FMR LLC now owns 35,248,665 shares of the company’s stock valued at $543,534,000 after acquiring an additional 10,766,729 shares during the period. Brahman Capital Corp. increased its stake in shares of Teva Pharmaceutical Industries by 67.3% during the fourth quarter. Brahman Capital Corp. now owns 12,248,106 shares of the company’s stock valued at $188,866,000 after acquiring an additional 4,925,245 shares during the period. Polaris Capital Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 4.4% during the fourth quarter. Polaris Capital Management LLC now owns 10,342,980 shares of the company’s stock valued at $159,489,000 after acquiring an additional 431,942 shares during the period. Norges Bank acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $146,130,000. Finally, Northern Trust Corp increased its stake in shares of Teva Pharmaceutical Industries by 1.1% during the first quarter. Northern Trust Corp now owns 6,763,360 shares of the company’s stock valued at $106,050,000 after acquiring an additional 75,596 shares during the period. Institutional investors own 65.10% of the company’s stock.

The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.66. The company has a market cap of $8.86 billion, a P/E ratio of 3.08, a P/E/G ratio of 1.09 and a beta of 1.64.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The business had revenue of $4.30 billion for the quarter, compared to analyst estimates of $4.38 billion. During the same quarter last year, the business earned $0.94 earnings per share. The business’s revenue for the quarter was down 15.2% on a year-over-year basis. Research analysts expect that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 1-Year Low After Analyst Downgrade” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/teva-pharmaceutical-industries-nyseteva-hits-new-1-year-low-after-analyst-downgrade/3040973.html.

Teva Pharmaceutical Industries Company Profile (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: Technical Analysis

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.